<div id="readability-page-1"><p>Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) is projected to release its  Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $5.2980 million for the quarter. Investors can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 3:00 AM ET.</p><div><p><span></span><span>Get <strong>Mereo BioPharma Group</strong> alerts:</span></p></div><ul><li>Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential</li></ul><p>Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last posted its earnings results on Thursday, March 19th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01).  On average, analysts expect Mereo BioPharma Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. </p><h2>Mereo BioPharma Group Stock Down 1.9%</h2><p>NASDAQ MREO opened at $0.34 on Wednesday. The firm has a market cap of $53.47 million, a P/E ratio of -5.60 and a beta of 0.34. The company's 50 day moving average is $0.43 and its 200-day moving average is $1.29. Mereo BioPharma Group has a 12-month low of $0.20 and a 12-month high of $3.05. </p><h2>Wall Street Analysts Forecast Growth</h2><p>MREO has been the topic of several recent research reports. Robert W. Baird  set a $1.00 target price on Mereo BioPharma Group in a research report on Monday, December 29th. Needham &amp; Company LLC cut their target price on Mereo BioPharma Group from $5.00 to $3.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, January 13th. Cantor Fitzgerald  reiterated an &#34;overweight&#34; rating on shares of Mereo BioPharma Group in a research report on Monday, December 29th. JPMorgan Chase &amp; Co.  reissued a &#34;neutral&#34; rating on shares of Mereo BioPharma Group in a report on Monday. Finally, Wall Street Zen cut shares of Mereo BioPharma Group from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, January 3rd. Three investment analysts have rated the stock with a Buy rating, four have assigned  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $3.25.</p><p><b>Get Our Latest Research Report on Mereo BioPharma Group</b></p><h2>More Mereo BioPharma Group News</h2><p>Here are the key news stories impacting Mereo BioPharma Group this week:</p><ul>   <li><span>Positive Sentiment: </span>Reported decline in short interest as of Mar 13 — short interest fell to 11,262,015 shares (down ~18.2% from Feb 26), representing ~7.5% shorted and a days‑to‑cover of ~7.9 on the stated average volume; shorter gross short exposure can remove some downward pressure on the stock. </li>    <li><span>Neutral Sentiment: </span>Conflicting short‑interest data for March 24 (multiple feeds showing 0 shares and NaN changes) suggests reporting anomalies; short‑interest metrics may be unreliable until confirmed. </li>    <li><span>Neutral Sentiment: </span>JPMorgan reaffirmed a “neutral” rating on MREO, which is neither bullish nor bearish and likely has limited immediate impact. <i></i><span>Benzinga</span></li>    <li><span>Negative Sentiment: </span>Multiple law firms have filed or are soliciting lead‑plaintiff participants in a securities class action (class period: 6/5/2023–12/26/2025) and are reminding investors of the April 6, 2026 deadline — this creates legal overhang, potential future liability, and selling pressure as investors reassess risk. See representative notices: Rosen Law Firm. <i></i><span>Rosen Law Firm</span> Pomerantz. <i></i><span>Pomerantz</span> Bronstein/Gewirtz. <i></i><span>Bronstein</span></li> </ul><h2>Institutional Investors Weigh In On Mereo BioPharma Group</h2><p>Large investors have recently added to or reduced their stakes in the company. Marex Group plc purchased a new position in shares of  Mereo BioPharma Group in the 2nd quarter worth about $27,000.  Virtu Financial LLC purchased a new position in shares of  Mereo BioPharma Group during the 3rd quarter valued at about $33,000.  Graham Capital Management L.P. bought a new stake in  Mereo BioPharma Group in the 4th quarter worth approximately $48,000.  Virtus Investment Advisers LLC boosted its stake in  Mereo BioPharma Group by 199.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 122,595 shares of the company's stock worth $51,000 after buying an additional 81,665 shares in the last quarter.  Finally, Squarepoint Ops LLC boosted its stake in  Mereo BioPharma Group by 45.4% in the third quarter. Squarepoint Ops LLC now owns 30,055 shares of the company's stock worth $62,000 after buying an additional 9,387 shares in the last quarter. Hedge funds and other institutional investors own  62.83% of the company's stock. </p><h2>Mereo BioPharma Group Company Profile</h2> (Get Free Report)<p>Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.  </p><p>Mereo's pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Mereo BioPharma Group</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJFTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJFTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Mereo BioPharma Group Right Now?</h2><p>Before you consider Mereo BioPharma Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mereo BioPharma Group wasn't on the list.</p><p>While Mereo BioPharma Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MREO

<p>Mereo BioPharma Group (NASDAQ:MREO) is set to release its Q4 2025 earnings on April 1, with analysts expecting a loss of ($0.01) per share and revenue of $5.298 million. The stock is currently down 1.9%, trading at $0.34, with a market cap of $53.47 million. Recent analyst ratings show a consensus of 'Hold' with a target price of $3.25. Legal challenges may impact investor sentiment, as multiple law firms are soliciting participants for a class action related to the company. Institutional investors hold 62.83% of the stock.</p>

Mereo BioPharma Group (MREO) Projected to Post Earnings on Wednesday